UK biotech innovation struggles to scale into industry
TechRadar says UK biotech innovation is strong in laboratories, but policy gaps, funding barriers and market obstacles stop it becoming industry.

Key takeaways
- TechRadar says the UK is strong at biotech invention but weaker at turning it into industrial production.
- The UK bioeconomy ranks fourth in Europe by value added, generating about £325 billion and supporting 6.4 million jobs.
- Bio-based products face barriers from established fossil-based supply chains, mixed policy signals and funding gaps for first-of-a-kind plants.
- The BioRevolution Coalition wants ministerial responsibility, tax review, consistent carbon accounting, public procurement and investment support.
In this article
The gap between invention and industry
UK biotech innovation is strong in research, according to TechRadar. The publisher made the argument in a 19 November 2026 article. It says the country is not always good at turning research into manufacturing businesses.
The article says scientists and engineers are finding biological ways to make chemicals and materials. These materials usually come from oil and gas. The problem is not a lack of ideas. It is the harder task of moving from a laboratory process to reliable production, investment and customers.
TechRadar says developing a promising technology is only the first step. The challenge is commercial. TechRadar argues that this is where the UK risks falling behind.
Why bio-based products face barriers

Biotechnology can use plants, algae, microorganisms and waste to make products. These resources can include agricultural or food waste. TechRadar says these products can include medicines, cleaning ingredients, packaging and industrial materials. One example is paracetamol.
The UK bioeconomy ranks fourth in Europe by value added. It generates around £325 billion and supports 6.4 million jobs. TechRadar says the bioeconomy is not only a niche sustainability concept. Its potential reaches beyond environmental policy.
Even so, new bio-based products must compete with fossil-based materials. Those materials have established supply chains, existing infrastructure and familiar rules. The market has long been shaped by fossil-based alternatives. That makes it harder for new materials to gain a foothold. Companies also need factories, equipment, skilled staff, finance and buyers. Buyers may be willing to try something new.
Celtic Renewables ferments leftovers from whisky production to create bio-based chemicals. Biome Bioplastics develops plant-based bioplastics for packaging and other uses. TechRadar says these examples show biotechnology moving beyond research. Yet biotech businesses are being held back from that transition.
TechRadar also notes that bio-based describes biological origin. Biodegradable and compostable describe what happens at the end of a product's life. These terms are not interchangeable. Each product must be judged on performance and environmental impact.
Mixed policy signals and funding gaps
TechRadar says responsibility for the bioeconomy is spread across government departments. It also says some tax and carbon-accounting rules can disadvantage bio-based alternatives. This can happen when rules favour established fossil-derived products. Such uncertainty makes long-term investment harder.
Companies need capital and predictable demand to scale. Investors and customers often want evidence of commercial scale before committing. TechRadar says the UK must bridge that gap.
A successful pilot plant does not automatically become a commercial factory. First-of-a-kind facilities can need large amounts of capital. This can be difficult before a company has a proven production record. TechRadar says public policy can support innovation in principle. But it can still leave incentives that favour incumbent technologies.
Five changes proposed by BioRevolution Coalition
The BioRevolution Coalition is calling for five policy changes. It is using a parliamentary petition to make its case.
First, it wants clear ministerial responsibility for the bioeconomy. This would give businesses a coordinated contact and a more consistent direction. Second, it wants tax and policy frameworks reviewed. The aim is to remove unintended disadvantages for bio-based products. Environmental and safety standards should remain appropriate.
Third, it wants consistent carbon-accounting methods. These would allow fair comparisons between bio-based and fossil-based materials. Fourth, it wants public procurement to create early demand. Public-sector buyers, including the NHS, could show that new materials work. Fifth, it wants help to attract investment for first-of-a-kind plants.
Why scaling matters for the UK
TechRadar says the UK could build a stronger industrial base around biotechnology. Advanced materials are part of this opportunity. This could support skilled jobs and attract investment. It could also improve supply-chain resilience. It could help reduce dependence on fossil resources. It could also open new markets for British industry.
But the outcome is not guaranteed. If Britain develops innovations without creating conditions for commercial use, it may export products. It may also export the economic value of making them. TechRadar says policy should help sound technologies compete fairly. It should not give special treatment regardless of performance.
Sources
Spotted a mistake? See our corrections policy. Read how News by OnDevice works in our editorial policy.



